Unidad de Investigación Clínica de Cáncer Pulmón H12O-CNIO

Inicio | Investigación e innovación | Programas Científicos | Programa de Investigación Clínica | Unidad de Investigación Clínica de Cáncer Pulmón H12O-CNIO

Luis Gonzaga Paz-Ares
Luis Gonzaga Paz-Ares Jefe de Unidad de Investigación Clínica
T +34 (+34) 917 328 000 (Ext )
lpazares@ext.cnio.es

Investigadores Científicos

  • María Teresa Agullo
  • Irene Ferrer
  • Itziar Otano
  • Beatriz Soldevilla

Investigador Clínico I

  • Juan Manuel Coya
  • Rocio García
  • José Luis Solórzano
  • Álvaro Conrado Ucero
  • Jon Zugazagoitia

Becarios Post-doctorales

  • María Magdalena Abraham
  • María Cristina Cirauqui
  • Jose Garrido
  • Arantza Lamas
  • Marcos Rubio
  • Miguel Ruiz
  • Gorka Ruiz de Garibay

Becarios Pre-Doctorales

  • Carlos Carretero
  • María Inés Díaz
  • María del Carmen Fernández-Luna
  • Santiago García
  • David Gómez
  • María Gutiérrez
  • Iván Hernández
  • Rita Manzano
  • Wajahat Nadeem
  • Ángel Núñez
  • Beatriz Rubio
  • Joan Salvador Russo
  • Alba Santos Ramos

Técnicos de Laboratorio

  • Vera Adradas
  • Eva Álvarez
  • Nuria Carrizo
  • Patricia Cozar
  • Laura García
  • Beatriz Gil
  • José María Gracia
  • Marta Jiménez
  • Patricia Llamas
  • Patricia Plaza
  • Belén Revuelta
  • Jacinto Sarmentero
  • Rocío Suárez
  • César Vélez

Lung cancer continues to be the most frequent cause of cancer-related deaths worldwide. Our Unit focuses on the study of lung cancer, with a pragmatic orientation, always aiming to solve the problems of lung cancer patients. We are particularly interested in 2 research areas: the identification of new molecular biomarkers for diagnostic, prognostic, and predictive purposes; and the development of novel treatment strategies, including targeted therapies and immunotherapeutics. For example, we have contributed to elucidating the molecular determinants of EGFR or FGFR oncogenicity and have discovered biomarkers that may guide the efficacy of inhibitors of those receptors in lung cancer. We have continued developing an extensive platform of patient-derived xenografts (PDXs) and organoids (PDOs) of non-small-cell and small cell lung cancers to test new therapeutic strategies. Finally, our Unit has extensive experience in taking new drugs to the clinic, as well as in conducting practice-changing phase 2/3 trials in the fields of personalised cancer care and immuno-oncology.

Publicaciones

Subir